Authors' reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study"
- PMID: 34705165
- DOI: 10.1007/s40257-021-00640-5
Authors' reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study"
Comment on
-
Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study.Am J Clin Dermatol. 2021 Nov;22(6):901-902. doi: 10.1007/s40257-021-00642-3. Epub 2021 Oct 27. Am J Clin Dermatol. 2021. PMID: 34705164 Free PMC article. No abstract available.
References
-
- Borg E, Thoning H. Comment on: “Drug survival of IL-12/23, IL- 17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi‑country, multicentric cohort study.” Am J Clin Dermatol. 2021. https://doi.org/10.1007/s40257-021-00642-3 - DOI - PubMed
-
- Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–79. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
